Main Menu

Edge Therapeutics, Inc.

(NASDAQ GS: EDGE)

Summary

Attention investors who purchased shares of Edge Therapeutics, Inc. before November 26, 2018:

Rigrodsky & Long is investigating potential claims against the board of directors of Edge Therapeutics, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by PDS Biotechnology Corporation.

Press Release

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Edge Therapeutics, Inc. (“Edge Therapeutics” or the “Company”) (NASDAQ GS: EDGE) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to merge with PDS Biotechnology Corporation (“PDS”).  Under the terms of the agreement, shareholders of Edge Therapeutics will own approximately 30% of the combined company.

If you own common stock of Edge Therapeutics and purchased any shares before November 26, 2018, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.  

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Back to Page